AIM ImmunoTech completes last dosing in Phase 2 DURIPANC trial of Ampligen plus AstraZeneca Imfinzi in metastatic pancreatic cancer
AIM•Last dosing completed in Phase 2 DURIPANC trial
AIM ImmunoTech completed last dosing in its Phase 2 DURIPANC trial of Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer.
Results have not been presented; primary endpoint analysis is set to start in December 2026, with topline data expected in Q1 2027.
The readout will indicate whether the combination can deliver meaningful disease control in this hard-to-treat setting.
Overall survival analysis is expected to begin in June 2027, a key inflection point for a potential Phase 3 program.
Earlier exploratory use in a Dutch named-patient program signaled a possible survival benefit in a biomarker-defined subgroup, pending confirmation in trials.
